

Rational Drug Therapy Program

WVBMS Drug Utilization Board

May 25, 2016



Presented by Stephen A. Small, M.S., R.Ph.

West Virginia University School of Pharmacy





January 2016 Program Summary

| EO/PA Status | EO Count | % of EO Total | PA Count | % of PA Total | Total Count |
|----------------------|-------------|---------------|-------------|---------------|-------------|
| APPROVED | 2276 | 71.26% | 2539 | 50.82% | 4815 |
| CALLTRACK | 0 | 0.00% | 289 | 5.78% | 289 |
| CANCEL | 0 | 0.00% | 9 | 0.18% | 9 |
| CLOSED | 58 | 1.82% | 167 | 3.34% | 225 |
| DENIED | 643 | 20.13% | 1549 | 31.00% | 2192 |
| INPROCESS | 0 | 3.60% | 48 | 0.96% | 48 |
| MEDREVIEW | 115 | 3.19% | 366 | 7.33% | 481 |
| PENDING | 102 | 3.19% | 29 | 0.58% | 131 |
| Total Program | 3194 | 40.65% | 4996 | 63.59% | 7367 |



February 2016 Program Summary

| EO/PA Status | EO Count | % of EO Total | PA Count | % of PA Total | Total Count | % of Total |
|----------------------|-------------|---------------|-------------|---------------|-------------|---------------|
| APPROVED | 2289 | 70.60% | 2643 | 53.56% | 4932 | 60.32% |
| CALLTRACK | 0 | 0.00% | 304 | 6.16% | 304 | 3.72% |
| CANCEL | 0 | 0.00% | 9 | 0.18% | 9 | 0.11% |
| CLOSED | 102 | 3.15% | 229 | 4.64% | 331 | 4.05% |
| DENIED | 631 | 19.46% | 1426 | 28.90% | 2057 | 25.16% |
| INPROCESS | 1 | 3.12% | 22 | 0.45% | 23 | 0.28% |
| MEDREVIEW | 101 | 3.64% | 299 | 6.06% | 400 | 4.89% |
| PENDING | 118 | 3.64% | 3 | 0.06% | 121 | 1.48% |
| Total Program | 3242 | 37.11% | 4935 | 56.49% | 8177 | 93.60% |
| # Member ID# s | 2423 | 1.34 | 4063 | 1.21 | 6486 | 1.26 |





■ PENDING ■ MEDREVIEW ■ INPROCESS ■ DENIED ■ CLOSED ■ CANCEL ■ CALLTRACK ■ APPROVED

■ PENDING ■ MEDREVIEW ■ INPROCESS ■ DENIED ■ CLOSED ■ CANCEL ■ CALLTRACK ■ APPROVED



March 2016 Program Summary

| EO/PA Status | EO Count | % of EO Total | PA Count | % of PA Total | Total Count | % of Total |
|-----------------------|-------------|---------------|-------------|---------------|--------------|---------------|
| APPROVED | 6789 | 86.20% | 2524 | 47.90% | 9313 | 70.85% |
| CALLTRACK | 0 | 0.00% | 281 | 5.33% | 281 | 2.14% |
| CANCEL | 0 | 0.00% | 18 | 0.34% | 18 | 0.14% |
| CLOSED | 134 | 1.70% | 625 | 11.86% | 759 | 5.77% |
| DENIED | 681 | 8.65% | 1511 | 28.68% | 2192 | 16.68% |
| INPROCESS | 3 | 2.35% | 25 | 0.47% | 28 | 0.21% |
| MEDREVIEW | 185 | 1.07% | 283 | 5.37% | 468 | 3.56% |
| PENDING | 84 | 1.07% | 2 | 0.04% | 86 | 0.65% |
| Total Program | 7876 | 56.99% | 5269 | 38.13% | 13145 | 95.12% |
| # Member ID# s | 4600 | 1.71 | 4262 | 1.24 | 9059 | 1.45 |





April 2016 Program Summary

| EO/PA Status | EO Count | % of EO Total | PA Count | % of PA Total | Total Count | % of Total |
|-----------------------|-------------|---------------|-------------|---------------|-------------|---------------|
| APPROVED | 2029 | 67.27% | 2271 | 50.56% | 4300 | 57.27% |
| CALLTRACK | 0 | 0.00% | 201 | 4.47% | 201 | 2.68% |
| CANCEL | 0 | 0.00% | 9 | 0.20% | 9 | 0.12% |
| CLOSED | 183 | 6.07% | 416 | 9.26% | 599 | 7.98% |
| DENIED | 618 | 20.49% | 1187 | 26.42% | 1805 | 24.04% |
| INPROCESS | 2 | 3.61% | 47 | 1.05% | 49 | 0.65% |
| MEDREVIEW | 109 | 2.49% | 279 | 6.21% | 388 | 5.17% |
| PENDING | 75 | 2.49% | 82 | 1.83% | 157 | 2.09% |
| Total Program | 3016 | 37.54% | 4492 | 55.91% | 7508 | 93.45% |
| # Member ID# s | 2260 | 1.33 | 3649 | 1.23 | 5909 | 1.27 |



January 2016 Edit Overrides (EO)



| EO Status | 7069 Therapy Duplication | 7073 Early Refill | 7026 Disp > Exceeds Max | 7187 Max Units Exceeded | 7071 Ingredient Duplication | 217 Incarcerated | 7196 Max Units Supply Limit |
|-------------------|--------------------------|-------------------|-------------------------|-------------------------|-----------------------------|------------------|-----------------------------|
| APPROVED | 1027 | 496 | 208 | 60 | 98 | 95 | 37 |
| CLOSED | 20 | 19 | 2 | 4 | 5 | 3 | 3 |
| DENIED | 238 | 108 | 80 | 38 | 4 | 1 | 46 |
| INPROCESS | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| MEDREVIEW | 36 | 13 | 9 | 7 | 0 | 0 | 9 |
| PENDING | 54 | 7 | 10 | 16 | 1 | 2 | 4 |
| Total EO's | 1375 | 643 | 309 | 125 | 108 | 101 | 99 |



■ PENDING
 ■ MEDREVIEW
 ■ INPROCESS
 ■ DENIED
 ■ CLOSED
 ■ APPROVED



February 2016 Edit Overrides (EO)

| EO Status | 7069 Therapy Duplication | 7073 Early Refill | 7026 Disp > Exceeds Max | 7187 Max Units Exceeded | 7196 Max Units Supply Limit | 7071 Ingredient Duplication |
|------------|--------------------------|-------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|
| APPROVED | 78.16% | 73.13% | 60.27% | 67.24% | 28.26% | 79.31% |
| CLOSED | 1.99% | 5.26% | 4.45% | 4.31% | 2.17% | 6.90% |
| DENIED | 13.46% | 18.42% | 28.77% | 14.66% | 60.87% | 9.20% |
| INPROCESS | 0.00% | 0.14% | 0.00% | 0.00% | 0.00% | 0.00% |
| MEDREVIEW | 1.76% | 1.11% | 2.74% | 3.45% | 6.52% | 2.30% |
| PENDING | 4.63% | 1.94% | 3.77% | 10.34% | 2.17% | 2.30% |
| Total EO's | 1360 | 722 | 292 | 116 | 92 | 87 |





March 2016 Edit Overrides (EO)

| Edit Override Status | 7091 Prescriber Not on File | 7069 Therapy Duplication | 7073 Early Refill | 7026 Disp > Exceeds Max | 7071 Ingredient Duplication | 7187 Max Units Exceeded |
|----------------------|-----------------------------|--------------------------|-------------------|-------------------------|-----------------------------|-------------------------|
| APPROVED | 98.16% | 77.63% | 75.90% | 66.22% | 88.52% | 71.15% |
| CLOSED | 1.26% | 2.22% | 4.26% | 4.01% | 1.64% | 0.00% |
| DENIED | 0.28% | 13.78% | 16.70% | 24.41% | 5.74% | 15.38% |
| INPROCESS | 0.02% | 0.07% | 0.00% | 0.00% | 0.00% | 0.96% |
| MEDREVIEW | 0.28% | 3.46% | 2.13% | 3.34% | 0.82% | 6.73% |
| PENDING | 0.00% | 2.84% | 1.01% | 2.01% | 3.28% | 5.77% |
| Total EO's | 4289 | 1444 | 892 | 299 | 122 | 104 |



April 2016 Edit Overrides (EO)

| EO Status | 7069 Therapy Duplication | 7073 Early Refill | 7026 Disp > Exceeds Max | 7071 Ingredient Duplication | 7196 Sum Qnty>Time | 217 Incarcerated Member |
|------------|--------------------------|-------------------|-------------------------|-----------------------------|--------------------|-------------------------|
| APPROVED | 69.98% | 75.31% | 54.13% | 86.41% | 30.95% | 80.49% |
| CLOSED | 7.11% | 4.94% | 9.50% | 1.94% | 3.57% | 14.63% |
| DENIED | 17.20% | 16.87% | 30.58% | 9.71% | 46.43% | 0.00% |
| INPROCESS | 0.08% | 0.00% | 0.41% | 0.00% | 0.00% | 0.00% |
| MEDREVIEW | 2.73% | 1.65% | 3.31% | 0.00% | 13.10% | 2.44% |
| PENDING | 2.89% | 1.23% | 2.07% | 1.94% | 5.95% | 2.44% |
| Total EO's | 1209 | 729 | 242 | 103 | 84 | 82 |




January 2016 Prior Approvals


| | Atypical Anti- psychotics | Anti- convulsants | ADD Agents | Narcotic Withdrawal | Amphet- amines |
|-----------|------------------------------|----------------------|------------|------------------------|-------------------|
| APPROVED | 71.61% | 67.10% | 32.46% | 85.16% | 65.49% |
| CALLTRACK | 3.03% | 4.44% | 1.97% | 8.20% | 9.41% |
| CANCEL | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| CLOSED | 4.15% | 3.92% | 4.92% | 1.17% | 0.78% |
| DENIED | 14.35% | 18.28% | 40.00% | 5.08% | 11.76% |
| INPROCESS | 1.59% | 0.52% | 0.00% | 0.00% | 0.39% |
| MEDREVIEW | 4.63% | 5.74% | 20.66% | 0.39% | 11.76% |
| PENDING | 0.64% | 0.00% | 0.00% | 0.00% | 0.39% |
| Totals | 627 | 383 | 305 | 256 | 255 |

| | β -Adrenergic Steroid Comb | DPP-4 Inhibitors | Proton Pump Inhibitors | Alpha-2 Rec. Agonist | Direct Factor XA Inhibitors |
|-----------|-------------------------------------|---------------------|---------------------------|-------------------------|--------------------------------|
| APPROVED | 2.81% | 46.95% | 27.05% | 77.23% | 82.83% |
| CALLTRACK | 1.61% | 3.05% | 7.38% | 0.99% | 5.05% |
| CANCEL | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| CLOSED | 0.40% | 1.83% | 13.93% | 1.98% | 3.03% |
| DENIED | 85.54% | 46.95% | 28.69% | 14.85% | 6.06% |
| INPROCESS | 0.00% | 0.00% | 0.82% | 0.00% | 0.00% |
| MEDREVIEW | 9.64% | 1.22% | 22.13% | 3.96% | 2.02% |
| PENDING | 0.00% | 0.00% | 0.00% | 0.99% | 1.01% |
| Totals | 249 | 164 | 122 | 101 | 99 |

January 2016 PA Status Graph



January 2016 PA Distribution




February 2016 PA Stats


| | Atypical Anti- psychotics | Narcotic Withdrawal Agents | Anti-convulsants | Amphet-amines |
|-----------|------------------------------|-------------------------------|------------------|---------------|
| APPROVED | 65.76% | 80.29% | 64.48% | 68.97% |
| CALLTRACK | 3.01% | 9.86% | 5.17% | 9.05% |
| CANCEL | 0.14% | 0.00% | 0.34% | 0.00% |
| CLOSED | 9.89% | 3.19% | 5.17% | 7.76% |
| DENIED | 16.62% | 5.22% | 19.31% | 9.05% |
| INPROCESS | 0.29% | 0.87% | 0.34% | 0.43% |
| MEDREVIEW | 4.15% | 0.58% | 5.17% | 4.74% |
| PENDING | 0.14% | 0.00% | 0.00% | 0.00% |
| Totals | 698 | 345 | 290 | 232 |

| | DPP-4 Inhibitors | ADD Agents | Insulin Enhancer (Actos) | Direct Factor XA Inhibitors |
|-----------|------------------|------------|-----------------------------|--------------------------------|
| APPROVED | 42.16% | 47.37% | 83.23% | 79.83% |
| CALLTRACK | 3.43% | 7.89% | 0.60% | 5.04% |
| CANCEL | 0.00% | 0.00% | 0.60% | 0.00% |
| CLOSED | 2.45% | 4.21% | 2.40% | 4.20% |
| DENIED | 49.51% | 26.32% | 12.57% | 7.56% |
| INPROCESS | 0.00% | 1.05% | 0.00% | 0.00% |
| MEDREVIEW | 2.45% | 13.16% | 0.60% | 3.36% |
| PENDING | 0.00% | 0.00% | 0.00% | 0.00% |
| Totals | 204 | 190 | 167 | 119 |

February 2016 PA Status Graph



February 2016 PA Distribution




March 2016 PA Stats


| | Atypical Anti- psychotics | Narcotic Withdrawal Agents | DPP-4 Inhibitors | Anti-convulsants |
|-----------|------------------------------|-------------------------------|------------------|------------------|
| APPROVED | 61.11% | 50.13% | 35.08% | 60.99% |
| CALLTRACK | 2.20% | 9.56% | 1.05% | 3.55% |
| CANCEL | 0.00% | 0.26% | 0.00% | 0.00% |
| CLOSED | 14.47% | 34.63% | 4.45% | 10.64% |
| DENIED | 19.64% | 3.62% | 58.64% | 21.28% |
| INPROCESS | 0.26% | 0.00% | 0.00% | 0.00% |
| MEDREVIEW | 2.33% | 1.81% | 0.79% | 3.55% |
| PENDING | 0.00% | 0.00% | 0.00% | 0.00% |
| Totals | 744 | 387 | 382 | 282 |

| | Amphet-amines | ADD Agents | Direct Factor XA Inhibitors | Narcotic Analgesics |
|-----------|---------------|------------|--------------------------------|------------------------|
| APPROVED | 55.29% | 42.13% | 75.69% | 47.57% |
| CALLTRACK | 2.75% | 7.61% | 2.08% | 3.88% |
| CANCEL | 0.00% | 0.00% | 0.69% | 0.97% |
| CLOSED | 25.49% | 16.24% | 12.50% | 21.36% |
| DENIED | 7.84% | 20.81% | 7.64% | 20.39% |
| INPROCESS | 0.00% | 0.51% | 0.00% | 0.00% |
| MEDREVIEW | 8.63% | 12.69% | 1.39% | 5.83% |
| PENDING | 0.00% | 0.00% | 0.00% | 0.00% |
| Totals | 255 | 197 | 144 | 103 |

March 2016 PA Status Graph



March 2016 PA Distribution




April 2016 PA Stats


| | Atypical Anti- psychotics | Anti-convulsants | Narcotic Withdrawal Agents | Amphet-amines |
|-----------|------------------------------|------------------|-------------------------------|---------------|
| APPROVED | 67.35% | 66.45% | 60.82% | 53.85% |
| CALLTRACK | 2.64% | 3.65% | 3.78% | 5.13% |
| CANCEL | 0.15% | 0.33% | 0.00% | 0.00% |
| CLOSED | 6.73% | 5.65% | 30.58% | 21.54% |
| DENIED | 15.08% | 16.94% | 3.44% | 10.26% |
| INPROCESS | 0.73% | 0.66% | 0.34% | 0.51% |
| MEDREVIEW | 5.12% | 3.99% | 0.69% | 8.72% |
| PENDING | 2.20% | 2.33% | 0.34% | 0.00% |
| Totals | 683 | 301 | 291 | 195 |

| | DPP-4 Inhibitors | ADD Agents | Direct Factor XA Inhibitors | Lipotropics |
|-----------|------------------|------------|--------------------------------|-------------|
| APPROVED | 44.97% | 51.05% | 75.68% | 15.00% |
| CALLTRACK | 2.12% | 5.59% | 2.70% | 1.00% |
| CANCEL | 0.00% | 0.00% | 0.90% | 0.00% |
| CLOSED | 5.82% | 11.19% | 13.51% | 1.00% |
| DENIED | 44.44% | 20.28% | 3.60% | 73.00% |
| INPROCESS | 0.53% | 0.00% | 1.80% | 0.00% |
| MEDREVIEW | 0.53% | 10.49% | 0.90% | 6.00% |
| PENDING | 1.59% | 1.40% | 0.90% | 4.00% |
| Totals | 189 | 143 | 111 | 100 |


April 2016 PA Status Graph



April 2016 PA Distribution



Monthly Utilization



Therapy Duplications by Class

| Class | Class Name | January | February | March | April | Total |
|--------------|---|----------------|-----------------|--------------|--------------|--------------|
| H3A | ANALGESICS, NARCOTICS | 242 | 216 | 270 | 227 | 955 |
| H2S | SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS) | 134 | 140 | 172 | 138 | 584 |
| H2V | TX FOR ATTENTION DEFICIT-HYPERACT(ADHD)/NARCOLEPSY | 214 | 131 | 129 | 110 | 584 |
| J5B | ADRENERGICS, AROMATIC, NON-CATECHOLAMINE | 134 | 112 | 122 | 93 | 461 |
| H7C | SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS) | 87 | 110 | 101 | 69 | 367 |
| S2B | NSAIDS, CYCLOOXYGENASE INHIBITOR TYPE | 47 | 49 | 62 | 41 | 199 |
| A4D | HYPOTENSIVES, ACE INHIBITORS | 30 | 57 | 51 | 34 | 172 |
| D4J | PROTON-PUMP INHIBITORS | 43 | 53 | 50 | 39 | 185 |
| H7T | ANTIPSYCHOTICS, ATYPICAL, DOPAMINE, & SEROTONIN ANTAG | 61 | 54 | 49 | 44 | 208 |
| C4G | INSULINS | 33 | 45 | 46 | 36 | 160 |
| A4B | HYPOTENSIVES, SYMPATHOLYTIC | 47 | 64 | 43 | 42 | 196 |

Therapeutic Duplication by Drug

| Code # | Medication Name | Strength | January | February | March | April | Total |
|---------------|--------------------------|-----------------|----------------|-----------------|--------------|--------------|--------------|
| 004222 | OXYCODONE HCL/APAP | 5 MG-325MG | 27 | 18 | 27 | 24 | 96 |
| 057892 | DULOXETINE HCL | 30 MG | 26 | 33 | 21 | 15 | 95 |
| 046214 | FLUOXETINE HCL | 20 MG | 21 | 20 | 28 | 23 | 92 |
| 047430 | HYDROCODONE/APAP | 5 MG-325MG | 16 | 19 | 27 | 25 | 87 |
| 057893 | DULOXETINE HCL | 60 MG | 16 | 22 | 25 | 23 | 86 |
| 048977 | OXYCODONE HCL/APAP | 10MG-325MG | 21 | 18 | 27 | 16 | 82 |
| 030623 | HYDROCODONE/APAP | 10MG-325MG | 25 | 23 | 20 | 13 | 81 |
| 027462 | PANTOPRAZOLE SODIUM | 40 MG | 16 | 21 | 21 | 13 | 71 |
| 046404 | VENLAFAXINE HCL | 75 MG | 19 | 16 | 18 | 16 | 69 |
| 000346 | CLONIDINE HCL | 0.1 MG | 16 | 21 | 11 | 19 | 67 |
| 047431 | HYDROCODONE/APAP | 7.5-325MG | 18 | 21 | 11 | 13 | 63 |
| 005000 | DEXTROAMPHET/AMPHETAMINE | 10 MG | 17 | 14 | 16 | 10 | 57 |
| 045981 | METHYLPHENIDATE HCL | 18 MG | 23 | 18 | 0 | 10 | 51 |
| 045982 | METHYLPHENIDATE HCL | 36 MG | 21 | 15 | 15 | 0 | 51 |
| 005001 | DEXTROAMPHET/AMPHETAMINE | 20 MG | 17 | 14 | 0 | 0 | 31 |

Other Programs

- Children Stimulant Program
- Diabetes Medication Program

Sedative Hypnotic

- Sedative/Hypnotic Program
 - Matches other state programs
 - Implementation not as noisy as anticipated
 - Suspected increase in utilization of trazadone
 - WVBMS has added flexibility to the reviews for easier reviews.

Benzodiazepine Limits/Duplications

- FDA approved dosing plus one dose except alprazolam
- Duplication with benzodiazepine sedative hypnotics

Issues

■ Any Questions?